secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2022-12-06T23:59:59+00:00
Accession:  0001193125-22-299475
Event type: debt
Sentiment:  neutral
Materiality: 0.35
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio Pharma amends loan agreement, terminates tranche 2 commitments
------------------------------------------------------------------------

- Second Amendment acknowledges prior prepayment satisfied mandatory prepayment requirement.
- Certain budgeted expenses excluded from cash proceeds subject to mandatory prepayment.
- Removed threshold amounts applicable to certain prepayment events.
- Lenders' tranche 2 commitments terminated; royalty financing up to 10% of net sales permitted.
- Royalty financing for Acoramidis remains exempt from prepayment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000119312522299475/0001193125-22-299475-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000119312522299475/d423428d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-299475

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer